Anzupgo (delgocitinib) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

EMBER'S LAST NAME: MEMBER'S FIRST NAME:					
	view (e.g., chart notes o	or lab data, to support th	r. Attach any additional documenta e authorization request). Informati		
			☐ URG	ENT	
MEMBER INFORMATIO	N				
LAST NAME:		FIRST NAME:	FIRST NAME:		
PHONE NUMBER:		DATE OF BIRTH:			
STREET ADDRESS:		•			
CITY:		STATE:	ZIP CODE:		
PATIENT INSURANCE	D NUMBER:				
☐ MALE ☐ FEMALE	HEIGHT (IN/CM):	WEIGHT (LB/KG):	ALLERGIES:		
PATIENT'S AUTHORIZE AUTHORIZED REPRESE	<u>IETHERAPEUTICS.CC</u> D REPRESENTATIVE (<u>OM/NOPP</u> (IF APPLICABLE):	I CAN BE FOUND AT THE		
		JWIDER			
PRESCRIBER INFORM	ATION				
LAST NAME:		FIRST NAME:	FIRST NAME:		
PRESCRIBER SPECIALTY:		EMAIL ADDRES	EMAIL ADDRESS:		
NPI NUMBER:		DEA NUMBER:	DEA NUMBER:		
PHONE NUMBER:		FAX NUMBER:	FAX NUMBER:		
STREET ADDRESS:					
CITY:		STATE:	STATE: ZIP CODE:		
REQUESTER (if different than prescriber):		OFFICE CONTA	OFFICE CONTACT PERSON:		
		-			
MEDICATION OR MEDI	CAL DISPENSING INF	ORMATION			
MEDICATION NAME:					
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REF	QUANTITY:		
☐ NEW THERAPY	RENEWAL	F RENEWAL: DATE T			
DURATION OF THERAF	Y (SPECIFIC DATES):				
Continued on next page					

©2017-2024 Prime Therapeutics Management LLC, a Prime Therapeutics company Prime Therapeutics Management – Commercial Clients. Revision Date: 11.1.25 CAT009



Anzupgo (delgocitinib) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST N	AME:			
	OTHER MEDICATIONS FOR THIS (CONDITION?			
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	DURATION OF THERAPY (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:			
2. LIST DIAGNOSES:		ICD-10:			
Chronic hand eczema(CHE)	ICD-10 Code(s):				
3. REQUIRED CLINICAL INFORMATO SUPPORT A PRIOR AUTHORIZ	ATION : PLEASE PROVIDE ALL REL ZATION.	EVANT CLINICAL INFORMATION			
Is patient going to be using drug	in combination with a clinical trial?	P ☐ Yes ☐ No			
Does patient have a diagnosis of moderate to severe chronic hand eczema (CHE) with the eczema limited to the hands? No Please submit documentation. Has the chronic hand eczema persisted for more than 3 months? Yes No Please submit					
documentation.		· —			
Has the chronic hand eczema returned twice or more within the last 12 months even after being treated with at least 2 different topical therapies? Yes No Please submit documentation.					
Is the prescriber a dermatologist	or an allergist? 🗌 Yes 🔲 No				
Has patient tried at least 2 different topical steroids? Yes No Please submit documentation.					
Has the patient tried at least one to Please submit documentation.	topical steroid AND one topical cal	cineurin inhibitor? Yes No			
Has the patient tried at least one to submit documentation.	topical steroid AND Eucrisa (crisab	oorole)? 🗌 Yes 🔲 No Please			
Has the patient tried at least one to submit documentation.	topical steroid AND Zoryve (roflum	ist)? ☐ Yes ☐ No Please			
Is patient taking another topical odocumentation.	or oral JAK inhibitor at the same tin	ne? 🗌 Yes 🔲 No Please submit			
Are there any other comments, di information the physician feels is	agnoses, symptoms, medications important to this review?	tried or failed, and/or any other			



Anzupgo (delgocitinib) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: MEMBER'S FIRST NAME:
Please note: Not all drugs/diagnosis are covered on all plans. This request may be denied unless all required information is received.
ATTESTATION: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.
Prescriber Signature or Electronic I.D. Verification: Date:
CONFIDENTIALITY NOTICE: The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program

Attn: CP-4201 P.O. Box 64811 St. Paul, MN 55164-0811 **Phone**: 877-228-7909

